HIGHMARK | HIGHMARK

Outpatient Medical Injectable Rituximab and Biosimilars Request Form . Fax to 833-581-1861 (Medical Benefit Only)

Member Name:_____

Member Date of Birth:_____

Member ID (UMI): _____ ☐ Medicare ☐ Commercial*

Ordering/Attending Provider Name: _____ NPI: _____

Ordering/Attending Provider Address:_____

Office Contact: _____ Phone #:_____ Fax #:_____

Servicing Facility/Vendor Name: _____ Facility NPI: _____

Servicing Facility/Vendor Address:_____

Requested Start Date of Service: _____ ICD10 Diagnosis Code(s): _____

DRUG INFORMATION (*please select one*)		
PREFERRED PRODUCTS FOR ONCOLOGY INDICATIONS	**PREFERRED PRODUCT FOR RHEUMATOID ARTHRITIS**	NON-PREFERRED**
☐ Ruxience (Q5119) ☐ Truxima (Q5115)	☐ Ruxience (Q5119) ☐ Truxima (Q5115)	☐ Rituxan (J9312) ☐ Riabni (Q5123) ☐ Rituxan Hycela* (J9311) **Has the member experienced a documented drug therapy failure or intolerance to the preferred products?** **Ruxience: ☐ Yes ☐ No** **Truxima: ☐ Yes ☐ No** *Rituxan Hycela policy requires the member to have received at least one full dose of a rituximab product by intravenous infusion **A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial of **BOTH** preferred products, or **BOTH** preferred products have not been tolerated or are contraindicated **Medicare members currently established on a non-preferred therapy are not required to try a preferred option.

****Please verify member's eligibility and benefits through the health plan****

Please answer the following for ONCOLOGY indications: ***(for non-oncology indications please proceed to question 6)***	
1. What type of cancer does the member have (include histology) and what stage disease?	
2. What is the member's chemotherapy regimen?	
3. What line of therapy is this considered (First, Second, Subsequent)?	
4. What previous therapies has the member received? (Please include if the member progressed or relapsed)	
5. Is the member's disease CD20-positive?	☐YES ☐NO ☐ NOT APPLICABLE
Please answer the following for a NON-ONCOLOGY indication: ***(In addition please make sure the accurate icd10 diagnosis code was given above)***	
6. What medications (if any) has the member previously used for this condition?	
7. What medications (if any) will the member be using in conjunction for the condition?	
8. What is the dose and frequency of the member's treatment?	Dose: _____ Frequency: _____
For Rheumatoid Arthritis indications ONLY 9. Is the member's RA moderately to severely active?	☐YES ☐NO

☐ **New Start**	☐ **Continuation of Therapy**
	Date of last infusion: _____
	Has the member demonstrated disease stability or a beneficial response to therapy? ☐ **YES** ☐ **NO**

Please attach all pertinent clinical information

Attached: ☐ **YES** ☐ **NO**

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.